Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab/Platinum/Etoposide in Advanced LCNEC
NCT05470595Phase 2Active, not recruiting
- Sponsor
- Technische Universität Dresden
- Start
- Jan 2022
- Primary completion
- Jan 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in large cell neuroendocrine carcinoma of the lung (LCNEC), sponsored by Technische Universität Dresden. Started Jan 2022; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
large cell neuroendocrine carcinoma of the lung (LCNEC)
Beyond the preview
Go deeper on NCT05470595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05470595.